
EquitySector - HealthcareVery High Risk
Regular
NAV (18-May-26)
Returns (Since Inception)
Fund Size
₹901 Cr
Expense Ratio
1.96%
ISIN
INF209KB1N91
Minimum SIP
₹1,000
Exit Load
1.00%
Inception Date
11 Jul 2019
In this section, we compare the returns of the scheme with the category average over various periods. Periods for which the fund has outperformed its category average are marked in green, otherwise red.
1 Year
+12.81%
+12.02% (Cat Avg.)
3 Years
+25.47%
+25.62% (Cat Avg.)
5 Years
+13.28%
+14.49% (Cat Avg.)
Since Inception
+19.24%
— (Cat Avg.)
| Equity | ₹888.32 Cr | 98.61% |
| Others | ₹12.56 Cr | 1.39% |
All Holdings
Equity
Debt & Others
| Name | Type | Amount | Holdings |
|---|---|---|---|
| Sun Pharmaceuticals Industries Ltd | Equity | ₹118.64 Cr | 13.17% |
| Apollo Hospitals Enterprise Ltd | Equity | ₹64.86 Cr | 7.20% |
| Torrent Pharmaceuticals Ltd | Equity | ₹42.87 Cr | 4.76% |
| J.B. Chemicals & Pharmaceuticals Ltd | Equity | ₹42.4 Cr | 4.71% |
| Aurobindo Pharma Ltd | Equity | ₹40.47 Cr | 4.49% |
| Ajanta Pharma Ltd | Equity | ₹36.5 Cr | 4.05% |
| Lupin Ltd | Equity | ₹36.01 Cr | 4.00% |
| Mankind Pharma Ltd | Equity | ₹34.95 Cr | 3.88% |
| Fortis Healthcare Ltd | Equity | ₹34.85 Cr | 3.87% |
| Abbott India Ltd | Equity | ₹32.9 Cr | 3.65% |
| Emcure Pharmaceuticals Ltd | Equity | ₹29.87 Cr | 3.32% |
| Cipla Ltd | Equity | ₹29.74 Cr | 3.30% |
| Ipca Laboratories Ltd | Equity | ₹25.8 Cr | 2.86% |
| Shilpa Medicare Ltd | Equity | ₹22.65 Cr | 2.51% |
| Corona Remedies Ltd | Equity | ₹20.2 Cr | 2.24% |
| Sai Life Sciences Ltd | Equity | ₹19.78 Cr | 2.20% |
| Alkem Laboratories Ltd | Equity | ₹18.92 Cr | 2.10% |
| Procter & Gamble Health Ltd | Equity | ₹18.36 Cr | 2.04% |
| Divi's Laboratories Ltd | Equity | ₹16.91 Cr | 1.88% |
| Jupiter Life Line Hospitals Ltd | Equity | ₹16.11 Cr | 1.79% |
| Sanofi Consumer Healthcare India Ltd | Equity | ₹15.03 Cr | 1.67% |
| Thyrocare Technologies Ltd | Equity | ₹14.19 Cr | 1.58% |
| Clearing Corporation Of India Limited | Cash - Repurchase Agreement | ₹13.48 Cr | 1.50% |
| Dr Reddy's Laboratories Ltd | Equity | ₹13.09 Cr | 1.45% |
| Metropolis Healthcare Ltd | Equity | ₹12.8 Cr | 1.42% |
| Alembic Pharmaceuticals Ltd | Equity | ₹12.16 Cr | 1.35% |
| Pfizer Ltd | Equity | ₹12.04 Cr | 1.34% |
| Jubilant Pharmova Ltd | Equity | ₹10.83 Cr | 1.20% |
| Anthem Biosciences Ltd | Equity | ₹10.77 Cr | 1.20% |
| Biocon Ltd | Equity | ₹9.77 Cr | 1.08% |
| Suraksha Diagnostic Ltd | Equity | ₹9.5 Cr | 1.06% |
| Piramal Pharma Ltd | Equity | ₹9.36 Cr | 1.04% |
| Medi Assist Healthcare Services Ltd | Equity | ₹9.02 Cr | 1.00% |
| Vijaya Diagnostic Centre Ltd | Equity | ₹8.83 Cr | 0.98% |
| Gland Pharma Ltd | Equity | ₹8.75 Cr | 0.97% |
| Dr. Lal PathLabs Ltd | Equity | ₹8.51 Cr | 0.94% |
| GlaxoSmithKline Pharmaceuticals Ltd | Equity | ₹7.66 Cr | 0.85% |
| Max Healthcare Institute Ltd Ordinary Shares | Equity | ₹6.95 Cr | 0.77% |
| Vinati Organics Ltd | Equity | ₹6.24 Cr | 0.69% |
| Net Receivables / (Payables) | Cash | ₹-0.93 Cr | 0.10% |
Large Cap Stocks
32.53%
Mid Cap Stocks
27.98%
Small Cap Stocks
38.09%
Equity Sector
Debt & Others
| Sector | Amount | Holdings |
|---|---|---|
| Healthcare | ₹882.07 Cr | 97.91% |
| Basic Materials | ₹6.24 Cr | 0.69% |
Standard Deviation
This fund
16.05%
Cat. avg.
16.62%
Lower the better
Sharpe Ratio
This fund
0.97
Cat. avg.
0.99
Higher the better
Sortino Ratio
This fund
--
Cat. avg.
1.77
Higher the better
Since July 2019
ISIN INF209KB1N91 | Expense Ratio 1.96% | Exit Load 1.00% | Fund Size ₹901 Cr | Age 6 years 10 months | Lumpsum Minimum ₹1,000 | Fund Status Open Ended Investment Company | Benchmark BSE Healthcare TR INR |
To seek to generate long-term capital growth from an actively managed portfolio primarily of Equity and Equity Related Securities. Scheme shall invest in Indian equities,foreign equities and related instruments and debt securities.
Note: As per the Income Tax Budget 2024, mutual funds are subject to capital gains taxation, which includes surcharge and cess based on prevailing income tax rules and the investor’s income. Taxation applies only to realised gains, not notional gains. Please consult your tax advisors to determine the implications or consequences of your investments in such securities.

Total AUM
₹3,94,519 Cr
Address
One World Centre, Tower 1, 17th Floor, Mumbai, 400 013
Your principal amount will be at Very High Risk

Download Dezerv App
Track and monitor all
your investments